Detalhe da pesquisa
1.
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Cephalalgia
; 43(11): 3331024231214987, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37987641
2.
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Headache
; 63(10): 1351-1358, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955395
3.
Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
Headache
; 63(7): 908-916, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37314065
4.
Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Eur J Neurol
; 29(7): 2129-2137, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302681
5.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Headache
; 61(9): 1376-1386, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374086
6.
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
Headache
; 60(10): 2444-2453, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33179323
7.
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study.
J Headache Pain
; 21(1): 109, 2020 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887548
8.
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
Adv Ther
; 40(2): 445-459, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36350532
9.
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Naunyn Schmiedebergs Arch Pharmacol
; 394(11): 2343-2346, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34581836